torudokimab (ZB-880) / Eli Lilly, Zura Bio - LARVOL DELTA

PIPELINE HIGHLIGHTS AND UPCOMING ANTICIPATED MILESTONES (Businesswire) - "Torudokimab:...The Company continues to monitor external clinical data from ongoing IL-33/ST2-targeted programs in asthma and chronic obstructive pulmonary disease, including Phase 2b and Phase 3 trials. An additional IL-33/ST2 data readout is expected in 2026."

Clinical data • Asthma • Chronic Obstructive Pulmonary Disease

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer (Businesswire) - "Concurrently, we're advancing...torudokimab towards Phase 2 readiness while closely monitoring external readouts expected in 2024....Additionally, the Company is monitoring Phase 2 and Phase 3 external catalysts in asthma and chronic obstructive pulmonary disease."

P2 data • Asthma • Chronic Obstructive Pulmonary Disease

Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok (Businesswire) - "Zura Bio Limited....today announced two abstracts were accepted and presented at World Allergy Congress (WAC), held December 1 – 3, 2023 in Bangkok, Thailand. The abstracts highlight Zura Bio’s informative research for ZB-168, an anti-IL-7Rα monoclonal antibody with potential across a broad set of indications where the IL-7 or TSLP pathways may be involved, and ZB-880 (torudokimab), a fully human, high affinity monoclonal antibody that neutralizes IL-33 and also has potential for a broad range of indications."

Biomarker • Clinical data • Atopic Dermatitis • Immunology

Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights (Businesswire) - "ZB-880 (torudokimab): Prepare to initiate Phase 2 trial of ZB-880, an anti-IL-33 antibody, for the treatment of asthma in 2024. Pending Phase 2 and Phase 3 external catalysts in asthma and chronic obstructive pulmonary disease."

New P2 trial • Asthma • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

Generation and Characterization of Torudokimab (LY3375880): A Monoclonal Antibody That Neutralizes Interleukin-33. (PubMed, J Inflamm Res) - "Torudokimab's half-life in cynomolgous monkey projects monthly dosing in the clinic. Due to torudokimab's high affinity, its ability to completely neutralize IL-33 activity in vitro and in vivo, and the observed cynomolgus monkey pharmacokinetic properties, this molecule was selected for clinical development."

Journal • Allergy • IL13 • IL33 • IL4 • IL5

ADmIRe: A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - P2; N=136; Terminated; Sponsor: Eli Lilly and Company; N=200 ➔ 136; Active, not recruiting ➔ Terminated; The study was terminated for lack of efficacy after an interim analysis was performed

Clinical • Enrollment change • Trial termination

ADmIRe: A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - P2; N=200; Active, not recruiting; Sponsor: Eli Lilly and Company; Trial completion date: Feb 2021 ➔ Feb 2020

Trial completion date

ADmIRe: A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - P2; N=200; Active, not recruiting; Sponsor: Eli Lilly and Company; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

A Study of Different Injectable Formulations of LY3375880 in Healthy Participants (clinicaltrials.gov) - P1; N=83; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed

Clinical • Trial completion

A Study of Different Injectable Formulations of LY3375880 in Healthy Participants (clinicaltrials.gov) - P1; N=74; Active, not recruiting; Sponsor: Eli Lilly and Company; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

A Study of Different Injectable Formulations of LY3375880 in Healthy Participants (clinicaltrials.gov) - P1; N=74; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open